NCT05652478View on ClinicalTrials.gov

Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions
Healthy VolunteerWeight GainMetabolic EffectsIntegrase Strand Transfer Inhibitors
Interventions
DRUG

Tenofovir alafenamide

25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.

DRUG

Dolutegravir

50mg dolutegravir (DTG) one tablet orally once daily for 8 days.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH